133 related articles for article (PubMed ID: 10517497)
1. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
Poloni A; Leoni P; Curzi L; Cantori I; Mancini S; Montanari M; Masia MC; Olivieri A
Exp Hematol; 1999 Oct; 27(10):1548-56. PubMed ID: 10517497
[TBL] [Abstract][Full Text] [Related]
2. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
[TBL] [Abstract][Full Text] [Related]
4. Use of amifostine in bone marrow purging.
Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
Douay L; Hu C; Giarratana MC; Gorin NC
Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
8. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Leukemia; 1998 Oct; 12(10):1596-602. PubMed ID: 9766505
[TBL] [Abstract][Full Text] [Related]
9. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
Douay L; Hu C; Giarratana MC; Gorin NC
Eur J Cancer; 1995; 31A Suppl 1():S14-6. PubMed ID: 7577094
[TBL] [Abstract][Full Text] [Related]
10. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
Skala JP; Rogers PC; Chan KW; Rodriguez WC
Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
[No Abstract] [Full Text] [Related]
12. Increased sensitivity of myeloid leukemia cell lines: potential of lovastatin as bone-marrow-purging agent.
Scheffold C; Schöttker B; Lefterova P; Csipai M; Glasmacher A; Huhn D; Neubauer A; Schmidt-Wolf IG
Acta Haematol; 2000; 104(2-3):72-9. PubMed ID: 11154978
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
[TBL] [Abstract][Full Text] [Related]
14. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
Widmer L; Pichert G; Jost LM; Stahel RA
Blood; 1996 Oct; 88(8):3166-75. PubMed ID: 8874217
[TBL] [Abstract][Full Text] [Related]
15. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
[TBL] [Abstract][Full Text] [Related]
16. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
17. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):58-63. PubMed ID: 8783669
[TBL] [Abstract][Full Text] [Related]
18. Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts.
Wierenga PK; Setroikromo R; Kamps G; Kampinga HH; Vellenga E
Exp Hematol; 2003 May; 31(5):421-7. PubMed ID: 12763141
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of the antitumor effect of Merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B.
Tsujino I; Miyagi K; Sampson RW; Sieber F
Photochem Photobiol; 2006; 82(2):458-65. PubMed ID: 16613499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]